Who
John Simard
Director and 10% owner
Company insider
Files Form 4 as: Chief Executive Officer, XBiotech.
In numbers
- Trades disclosed
- 50
- Buys
- 1
- Sells
- 20
- Bought
- $711K
- Sold
- $5.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Mar 2016
- Last trade
- 26 Oct 2026
- Last filed
- 28 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Oct 2026filed 28 Oct 2026 | XBIT XBiotechBiotechnology | SEC FORM 4 Bought | $711K368,524 at $1.93 | filing |
| 17 Mar 2025filed 19 Mar 2025 | XBIT XBiotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,026,228 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | XBIT XBiotechoption or derivative · Biotechnology | SEC FORM 4 Code J | $24.70T2,470,355 at $10,000,000.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | XBIT XBiotechoption or derivative · Biotechnology | SEC FORM 4 Code P | $24.70T2,470,355 at $10,000,000.00 | filing |
| 18 Oct 2021filed 15 Feb 2022 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $431K33,000 at $13.07 | filing |
| 15 Oct 2021filed 15 Feb 2022 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $226K17,000 at $13.32 | filing |
| 14 Oct 2021filed 15 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $273K21,125 at $12.90 | filing |
| 13 Oct 2021filed 15 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $140K10,875 at $12.83 | filing |
| 12 Oct 2021filed 15 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $230K18,000 at $12.77 | filing |
| 7 Oct 2021filed 15 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $489K39,286 at $12.45 | filing |
| 6 Oct 2021filed 6 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $134K10,714 at $12.53 | filing |
| 5 Oct 2021filed 6 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $180K14,218 at $12.66 | filing |
| 4 Oct 2021filed 6 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $310K23,681 at $13.08 | filing |
| 1 Oct 2021filed 1 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $260K19,684 at $13.23 | filing |
| 30 Sep 2021filed 1 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $243K18,558 at $13.07 | filing |
| 29 Sep 2021filed 1 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $220K16,396 at $13.41 | filing |
| 28 Sep 2021filed 1 Oct 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $89K6,263 at $14.27 | filing |
| 27 Sep 2021filed 28 Sep 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $443K29,890 at $14.81 | filing |
| 24 Sep 2021filed 28 Sep 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $165K11,418 at $14.49 | filing |
| 23 Sep 2021filed 28 Sep 2021 | XBIT XBiotechBiotechnology | SEC FORM 4 Sold | $145K9,892 at $14.68 | filing |
News
XBiotech's TASKIN Trial Meets Primary Efficacy Criterion In Metastatic Colorectal CancerXBIT · rttnews.com · 19 Oct 2026
0 headlines in the last 90 days name John Simard; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.